SARS-CoV-2 Vaccination and Risk of Severe COVID-19 Outcomes in Patients with Autoimmune Hepatitis

Background: Data regarding outcome of Coronavirus disease 2019 (COVID-19) in vaccinated patients with autoimmune hepatitis (AIH) are lacking. We evaluated the outcome of COVID-19 in AIH patients who received at least one dose of Pfizer- BioNTech (BNT162b2), Moderna (mRNA-1273) or AstraZeneca (ChAdOx1-S) vaccine.

Patients And Methods: We performed a retrospective study on AIH patients with COVID-19. The outcomes of AIH patients who had acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection after at least one dose of COVID-19 vaccine were compared to unvaccinated patients with AIH. COVID-19 outcome was classified according to clinical state during the disease course as: (i) no hospitalization, (ii) hospitalization without oxygen supplementation, (iii) hospitalization with oxygen supplementation by nasal cannula or mask, (iv) intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v) ICU admission with invasive mechanical ventilation or (vi) death, and data was analyzed using ordinal logistic regression.

Results: We included 413 (258 unvaccinated and 155 vaccinated) patients (81%, female) with a median age of 52 (range: 17-85) years at COVID-19 diagnosis. The rates of hospitalization were (36.4% vs. 14.2%), need for any supplemental oxygen (29.5% vs. 9%) and mortality (7% vs. 0.6%) in unvaccinated and vaccinated AIH patients with COVID-19. Having received at least one dose of SARS-CoV-2 vaccine was associated with a significantly lower risk of worse COVID-19 severity, after adjusting for age, sex, comorbidities and presence of cirrhosis (adjusted odds ratio [aOR] 0.18, 95% confidence interval [CI], 0.10-0.31). Overall, vaccination against SARS-CoV-2 was associated with a significantly lower risk of mortality from COVID-19 (aOR 0.20, 95% CI 0.11-0.35).

Conclusions: SARS-CoV-2 vaccination significantly reduced the risk of COVID-19 severity and mortality in patients with AIH.

Citing Articles

Autoimmune hepatitis under the COVID-19 veil: an analysis of the nature of potential associations.

Yu C, Wang W, Zhang Q, Jin Z Front Immunol. 2025; 16:1510770.

PMID: 39958350 PMC: 11825795. DOI: 10.3389/fimmu.2025.1510770.

Liver function abnormality on admission predicts long COVID syndrome in digestive system.

Wu H, Zhang Y, Tang W, Lv M, Chen Z, Meng F Heliyon. 2024; 10(19):e37664.

PMID: 39386803 PMC: 11462002. DOI: 10.1016/j.heliyon.2024.e37664.

COVID-19 Vaccination in Liver Cirrhosis: Safety and Immune and Clinical Responses.

Canha I, Silva M, Azevedo Silva M, Costa M, Saraiva R, Ruge A GE Port J Gastroenterol. 2024; 31(5):325-337.

PMID: 39360169 PMC: 11444661. DOI: 10.1159/000534740.

Insight into COVID-19 associated liver injury: Mechanisms, evaluation, and clinical implications.

Nasir N, Khanum I, Habib K, Wagley A, Arshad A, Majeed A Hepatol Forum. 2024; 5(3):139-149.

PMID: 39006140 PMC: 11237249. DOI: 10.14744/hf.2023.2023.0025.

Unveiling the future of COVID-19 patient care: groundbreaking prediction models for severe outcomes or mortality in hospitalized cases.

Hien N, Tsai F, Chang Y, Burton W, Phuc P, Nguyen P Front Med (Lausanne). 2024; 10:1289968.

PMID: 38249981 PMC: 10797111. DOI: 10.3389/fmed.2023.1289968.

References

Wu Z, McGoogan J . Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. DOI: 10.1001/jama.2020.2648. View

Efe C, Dhanasekaran R, Lammert C, Ebik B, Higuera-De La Tijera F, Aloman C . Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study. Hepatology. 2021; 73(6):2099-2109. PMC: 8250536. DOI: 10.1002/hep.31797. View

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J . Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720. PMC: 7092819. DOI: 10.1056/NEJMoa2002032. View

Khandker S, Godman B, Jawad M, Meghla B, Tisha T, Khondoker M . A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues. Vaccines (Basel). 2021; 9(12). PMC: 8708628. DOI: 10.3390/vaccines9121387. View

Baden L, El Sahly H, Essink B, Kotloff K, Frey S, Novak R . Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020; 384(5):403-416. PMC: 7787219. DOI: 10.1056/NEJMoa2035389. View

Galmiche S, Luong Nguyen L, Tartour E, de Lamballerie X, Wittkop L, Loubet P . Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review. Clin Microbiol Infect. 2022; 28(2):163-177. PMC: 8595936. DOI: 10.1016/j.cmi.2021.09.036. View

Yapali S . What hepatologists need to know about COVID-19?. Hepatol Forum. 2022; 1(2):41-43. PMC: 9349341. DOI: 10.14744/hf.2020.2020.0011. View

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497-506. PMC: 7159299. DOI: 10.1016/S0140-6736(20)30183-5. View

Chauhan M, Nzeako I, Li F, Thuluvath P . Antibody response after a booster dose of SARS-CoV-2 vaccine in liver transplant recipients and those with chronic liver diseases. Ann Hepatol. 2022; 27(4):100702. PMC: 8942457. DOI: 10.1016/j.aohep.2022.100702. View

10.

Moon A, Webb G, Garcia-Juarez I, Kulkarni A, Adali G, Wong D . SARS-CoV-2 Infections Among Patients With Liver Disease and Liver Transplantation Who Received COVID-19 Vaccination. Hepatol Commun. 2021; 6(4):889-897. PMC: 8652790. DOI: 10.1002/hep4.1853. View

11.

Efe C, Kulkarni A, Beretta-Piccoli B, Magro B, Stattermayer A, Cengiz M . Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role of corticosteroid therapy and outcome. Hepatology. 2022; 76(6):1576-1586. PMC: 9348326. DOI: 10.1002/hep.32572. View

12.

John B, Deng Y, Schwartz K, Taddei T, Kaplan D, Martin P . Postvaccination COVID-19 infection is associated with reduced mortality in patients with cirrhosis. Hepatology. 2022; 76(1):126-138. PMC: 9015228. DOI: 10.1002/hep.32337. View

13.

Kabacam G, Wahlin S, Efe C . Autoimmune hepatitis triggered by COVID-19: A report of two cases. Liver Int. 2021; 41(10):2527-2528. PMC: 8662284. DOI: 10.1111/liv.15044. View

14.

John B, Deng Y, Scheinberg A, Mahmud N, Taddei T, Kaplan D . Association of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis. JAMA Intern Med. 2021; 181(10):1306-1314. PMC: 8278308. DOI: 10.1001/jamainternmed.2021.4325. View

15.

Pascolini S, Vannini A, Deleonardi G, Ciordinik M, Sensoli A, Carletti I . COVID-19 and Immunological Dysregulation: Can Autoantibodies be Useful?. Clin Transl Sci. 2020; 14(2):502-508. PMC: 7536986. DOI: 10.1111/cts.12908. View

16.

Efe C, Lammert C, Tascilar K, Dhanasekaran R, Ebik B, Higuera-De La Tijera F . Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis. Liver Int. 2021; 42(3):607-614. DOI: 10.1111/liv.15121. View

17.

Onder G, Rezza G, Brusaferro S . Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. 2020; 323(18):1775-1776. DOI: 10.1001/jama.2020.4683. View

18.

Duengelhoef P, Hartl J, Ruther D, Steinmann S, Brehm T, Weltzsch J . SARS-CoV-2 vaccination response in patients with autoimmune hepatitis and autoimmune cholestatic liver disease. United European Gastroenterol J. 2022; 10(3):319-329. PMC: 9004241. DOI: 10.1002/ueg2.12218. View

19.

Fix O, Blumberg E, Chang K, Chu J, Chung R, Goacher E . American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease. Hepatology. 2021; 74(2):1049-1064. PMC: 8014184. DOI: 10.1002/hep.31751. View

20.

Polack F, Thomas S, Kitchin N, Absalon J, Gurtman A, Lockhart S . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27):2603-2615. PMC: 7745181. DOI: 10.1056/NEJMoa2034577. View